With a focus on the patient, EUROIMMUN develops and produces state-of-the-art test systems as one of the word’s leading manufacturers of medical laboratory diagnostics to aid in the diagnosis of diseases, as well as innovative automation and software solutions for effective and reliable processing and evaluation of such tests.
EUROIMMUN has its finger on the pulse of neurology through active basic research, a comprehensive and unique range of tests for the detection of neurobiomarkers, which is constantly being expanded on the basis of this research, and a service portfolio characterised by complete solutions for every laboratory.
Discover our contribution to research
Patient-oriented fundamental research is a priority of EUROIMMUN. Our “Institute for Experimental Immunology” maintains collaborations with universities, clinics and renowned research facilities worldwide in order to study new antigens and develop innovative methods. This provides the foundation for the development of new test systems.
Patient storys - Anti-NMDAR encephalitis
A new method for the identification of new target antigens in neurological autoimmune diseases:
Scharf M, et al. A spectrum of neural autoantigens, newly identified by histo-immunoprecipitation, mass spectrometry and recombinant cell-based indirect immunofluorescence. Frontiers Immunol 9:1447 (2018).
Discovery of septin-3 as an autoantibody target in patients with paraneoplastic cerebellar syndromes:
Miske R, et al. Septin-3 autoimmunity in patients with paraneoplastic cerebellar ataxia. J Neuroinflammation 20(1):88 (2023).
Guidelines for the preanalytical handling of CSF samples in order to reduce variability in measurement results:
Hansson O, et al. The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid beta and tau. Alzheimers Dement 17(9):1575-1582 (2021).
List of references
Important research contributions of EUROIMMUN in scientific articles of the last 5 years:
- Arlt FA et al. KCNA2 IgG autoimmunity in neuropsychiatric diseases. Brain Behav Immun 117:399-411 (2024)
- Khatib L, et al. Autoimmune cerebellar ataxia associated with anti-glutamate receptor δ2 antibodies: a rare but treatable entity. Cerebellum 23(1):260-266 (2024).
- Daguano Gastaldi V, et al. Factors predisposing to humoral autoimmunity against brain-antigens in health and disease: Analysis of 49 autoantibodies in over 7000 subjects. Brain Behav Immun 108:135-147 (2023).
- Discovery of Septin-3 as an autoantibody target in patients with paraneoplastic cerebellar syndromes:
Miske R, et al. Septin-3 autoimmunity in patients with paraneoplastic cerebellar ataxia. J Neuroinflammation 20(1):88 (2023). - Vilaseca A, et al. The expanding spectrum of antibody-associated cerebellar ataxia: report of two new cases of anti-AP3B2 ataxia. J Neurol 270(9):4533-4537 (2023).
- Identification of anti-septin-7 autoantibodies in patients with encephalopathy and myelopathy:
Hinson SR, et al. Septin-5 and -7-IgGs: Neurologic, Serologic, and Pathophysiologic Characteristics. Ann Neurol 92(6):1090-1101 (2022). - Jarius S, et al. Inositol 1,4,5-trisphosphate receptor type 1 autoantibody (ITPR1-IgG/anti-Sj)-associated autoimmune cerebellar ataxia, encephalitis and peripheral neuropathy: review of the literature. J Neuroinflammation 19(1):196 (2022).
- Jarius S, et al. Rho GTPase-activating protein 10 (ARHGAP10/GRAF2) is a novel autoantibody target in patients with autoimmune encephalitis. Neurol 269(10):5420-5430 (2022).
- McKeon-Makki I, et al. Adenylate kinase 5 (AK5) autoimmune encephalitis: Clinical presentations and outcomes in three new patients. J Neuroimmunol 367:577861 (2022).
- Álvarez I, et al. Added value of cerebrospinal fluid multimarker analysis in diagnosis and progression of dementia. Eur J Neurol 28(4):1142-1152 (2021)
- Cirkel A, et al. Paraneoplastic encephalomyeloradiculitis with multiple autoantibodies against ITPR-1, GFAP and MOG: case report and literature review. Neurol Res Pract 3(1):48 (2021)
- International guidelines for the preanalytical handling of CSF samples in order to reduce variability in measurement results:
Hansson O, et al. The Alzheimer’s Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid beta and tau. Alzheimers Dement 17(9):1575-1582 (2021) - Identification of AP3B2 as an autoantigen in patients with ataxia:
Honorat JA, et al. Autoimmune gait disturbance accompanying adaptor protein-3B2-IgG. Neurology 93(10):e954-e963 (2019) - Evidence forthe association between autoantibodies against RGS8 and paraneoplastic cerebellar syndrome with lymphoma:
Miske R, et al. Autoantibodies against the Purkinje cell protein RGS8 in paraneopastic cerebellar syndrome. Neurol Neuroimmunol Neuroinflamm 8(3):e987 (2021) - Schanda K, et al. Differential binding of autoantibodies to MOG isoforms in inflammatory demyelinating diseases. Neurol Neuroimmunol Neuroinflamm 8(5):e1027 (2021)
- Boulo S, et al. First amyloid β1-42 certified reference material for re-calibrating commercial immunoassays. Alzheimers Dement 16(11):1493-1503 (2020).
- Dubey D, et al. Contactin-1 autoimmunity: Serologic, neurologic, and pathologic correlates. Neurol Neuroimmunol Neuroinflamm 7(4):e771 (2020).
- Hall S, et al. Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders. Mov Disord 35(3):513-518 (2020).
- Jarius S, et al. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients. J Neuroinflammation 17(1):261 (2020).
- Bartels F, et al. Neuronal autoantibodies assiciated with cognitive impairment in melanoma patients. Ann Oncol 30(5):823-829 (2019).
- De Schaepdryver M, et al. Serum neurofilament heavy chains as early marker of motor neuron degeneration. Ann Clin Transl Neurol 6(10):1971-1979 (2019).
- Janelidze S, et al. Towards a unified protocol for handling of CSF before beta-amyloid measurements. Alzheimers Res Ther 11(1):63 (2019).
- O’Connor K, et al. GABAA receptor autoimmunity: A multicenter experience. Neurol Neuroimmunol Neuroinflamm 6(3):e552 (2019).
- Schumacher M, et al. Encephalopathy associated with neurochondrin autoantibodies. J Child Neurol 34(11):660-665 (2019).
- Confirmation of neurochondrin as an autoantigen in further cases of neurological autoimmunity:
Shelly S, et al. Neurochondrin neurological autoimmunity. Neurol Neuroimmunol Neuroinflamm 6(6), pii: e612 (2019). - Palmqvist S, et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer’s disease. EMBO Mol Med. 11(12):e11170 (2019).
- De Schaepdryver M, et al. Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 89(4):367-373 (2018).
- Lütt A, et al. High prevalence and functional effects of serum antineuronal antibodies in patients with gastrointestinal disorders. Neurogastroenterol Motil 30(6):e13292 (2018).
- Kirsebom BE, et al. Cerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement (NY) 4:617-627 (2018).
- Palmqvist S, et al. Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer’s disease: Crossvalidation study of practical algorithms. Alzheimers Dement: S1552-5260(18)33524-6 (2018).
- A new method for the identification of new target antigens in neurological autoimmune diseases:
Scharf M, et al. A spectrum of neural autoantigens, newly identified by histo-immunoprecipitation, mass spectrometry and recombinant cell-based indirect immunofluorescence. Frontiers Immunol 9:1447 (2018).
- Alfugham N, et al. ITPR1 autoimmunity: Frequency, neurologic phenotype, and cancer association. Neurol Neuroimmunol Neuroinflamm 5(1):e418 (2017).
- Berzero G, et al. Paraneoplastic cerebellar degeneration associated with anti-ITPR1 antibodies. Neurol Neuroimmunol Neuroinflamm 4(2):e326 (2017).
- Identification of anti-flotillin 1/2 autoantibodies in multiple sclerosis:
Hahn S, et al. Identification of the flotillin-1/2 heterocomplex as a target of autoantibodies in bona fide multiple sclerosis. J Neuroinflammation 14(1):123 (2017). - Honorat JA, et al. IgLON5 antibody: neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm 4(5):e385 (2017).
- Lang B, et al. Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies. J Neurol Neurosurg Psychiatry 88(4):353-361 (2017).
- Popkirov S, et al. Rho-associated protein kinase 2 (ROCK2): a new target of autoimmunity in paraneoplastic encephalitis. Acta Neuropathol Commun 5(1):40 (2017).
- Rommel FR, et al. Chorea minor associated with anti-neurochondrin autoantibodies. Neuropediatrics 48(6):482-483 (2017).
- Wilemse E, et al. How to handle adsorption of cerebrospinal fluid amyloid β (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the Aβ42/Aβ40 ratio. Alzheimers Dement. 13(8):885-892 (2017).
Discover our unparalleled spectrum of neurobiomarkers
EUROIMMUN offers a unique portfolio of test systems for the diagnostics of neurological diseases. Discover our spectrum of analysis parameters for the areas of CNS infections, neuronal autoimmunity and neurodegeneration that allow you to determine...
Autoimmune diagnostics
… more than 60 autoantibodies against neural structures, including new and exclusive parameters.
Infection diagnostics
… CXCL13 and intrathecal antibodies against many different pathogens.
Neurodegeneration
… beta-amyloids, tau proteins and neurofilaments (plus further research parameters).
EUROIMMUN – The Neuro Company
From research to all-round solutions for laboratories: Take a look behind the scenes and get to know highly motivated EUROIMMUNERs and their valuable contribution to neurodiagnostics.
Discover our solutions for diagnostics
Benefit from complete solutions for your laboratory: We offer not only a wide spectrum of diagnostic assays, but also innovative automation systems to meet your needs. Less hands-on time, more capacity. And you can count on our extensive advice and continuous support.
